Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease

NCT07718659 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT07718659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07718659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease
Lead sponsor
Qianfoshan Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2030
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd), parkinsonian disorders